SIGA Technologies Inc (SIGA)
NASDAQ:SIGA
Want to see SIGA full AI Analyst Report?
Top Page
SIGA Technologies
(NASDAQ:SIGA)
Select Model
Select Model
Rating:56Neutral
Price Target:
$4.50
▼(-33.53% Downside)
Action:Reiterated
Date:05/09/26
The score reflects mixed fundamentals: strong liquidity, no debt, and positive cash flow are meaningful supports, but they are tempered by sharp recent revenue declines and a very large TTM reported net loss. The latest earnings call adds modest upside via near-term delivery guidance and pipeline progress, while technicals indicate only a short-term rebound within a longer-term downtrend and valuation inputs are limited by a non-meaningful P/E and missing dividend yield.
Positive Factors
Strong liquidity and no debt
A ~ $146M cash balance and zero reported debt provide durable financial flexibility and a multi-quarter runway even after a special dividend. This supports continued manufacturing readiness, optional capital deployment, and R&D/pipeline funding despite uneven revenue cadence.
Negative Factors
Sharp revenue contraction
Steep multi-period revenue declines (≈32% in 2025 and ~84% TTM) signal demand concentration and vulnerability to procurement timing. Sustained or recurrent declines would erode operating leverage, challenge margin sustainability, and heighten execution risk for commercialization investments.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong liquidity and no debt
A ~ $146M cash balance and zero reported debt provide durable financial flexibility and a multi-quarter runway even after a special dividend. This supports continued manufacturing readiness, optional capital deployment, and R&D/pipeline funding despite uneven revenue cadence.
Read all positive factors
SIGA Technologies (SIGA) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$335.67M
Dividend YieldN/A
Average Volume (3M)461.52K
Price to Earnings (P/E)―
Beta (1Y)1.41
Revenue Growth-22.07%
EPS Growth-58.28%
CountryUS
Employees46
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)0.29
Shares Outstanding71,724,100
10 Day Avg. Volume376,632
30 Day Avg. Volume461,516
Financial Highlights & Ratios
PEG Ratio-0.31
Price to Book (P/B)2.20
Price to Sales (P/S)4.62
P/FCF Ratio10.15
Enterprise Value/Market Cap0.57
Enterprise Value/Revenue2.03
Enterprise Value/Gross Profit3.11
Enterprise Value/Ebitda7.78
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)1.7
Revenue Forecast (FY)$226.55M
SIGA Technologies Business Overview & Revenue Model
Company Description
SIGA Technologies, Inc., a commercial-stage pharmaceutical company, focuses on the health security and infectious disease markets in the United States. Its lead product is TPOXX, an oral formulation antiviral drug for the treatment of human smallp...
How the Company Makes Money
SIGA makes money primarily by selling its antiviral TPOXX (tecovirimat) under procurement and supply arrangements, historically driven largely by government demand for national stockpiles and outbreak response. Key revenue streams include: (1) Pro...
SIGA Technologies Earnings Call Summary
Earnings Call Date:May 07, 2026
(Q1-2026)
| % Change Since: |
Next Earnings Date:Jul 30, 2026
Earnings Call Sentiment Positive
The call presents a generally positive strategic and financial position driven by a strong cash balance, shareholder-friendly capital return, confirmed near-term international orders, regional commercial expansion via an exclusive Hikma agreement, and concrete pipeline progress (pediatric IND and PEP pathway). Offsetting these positives are the quarter's minimal deliveries and lumpy revenue profile, a small quarterly loss, a CHMP recommendation to withdraw the MPOXX indication in Europe, and slower progress toward a new U.S. government contract. Overall, the positives (liquidity, contracts, partnerships, and pipeline momentum) outweigh the near-term operational and regulatory headwinds.Positive Updates
Strong liquidity and balance sheet
Cash balance of approximately $146 million as of 03/31/2026 with no debt; pro forma cash would remain over $100 million after the special dividend, supporting runway and optional capital deployment.
Negative Updates
Quarterly revenue variability and minimal Q1 deliveries
First quarter had minimal product deliveries; Q1 product revenues included approximately $1 million of IV TPOXX deliveries to the SNS and about $2 million of reimbursement revenues, plus ~$3 million in R&D revenues — highlighting the lumpy, variable rhythm of the business.
Read all updates
Q1-2026 Updates
Positive
Negative
Strong liquidity and balance sheet
Cash balance of approximately $146 million as of 03/31/2026 with no debt; pro forma cash would remain over $100 million after the special dividend, supporting runway and optional capital deployment.
Read all positive updates
Company Guidance
Management reiterated that results are lumpy and should be viewed over the long term, and guided Q2 product revenues to include approximately $13.0 million of oral TPOXX to an international customer plus additional IV TPOXX deliveries to the SNS; Q1 product revenues comprised roughly $1.0M of IV deliveries to the SNS and ~$2.0M of reimbursement related to manufacturing tech transfer, with ~$3.0M of R&D revenue. Financial metrics for the quarter ended 03/31/2026 included a pretax operating loss of ~ $5.0M, net loss of ~ $3.0M, and fully diluted loss per share of $0.05; the company had cash of ~ $146.0M, no debt, and declared a special cash dividend of $0.60 per share (declared March 26, record April 7, paid April 23). Pipeline and timing guidance: $27.0M of 2025 funding supports pediatric formulation and IV tech transfer work, a 2025 IV order was received, a pediatric IND was filed and a Phase 1 study is underway with results expected in H2 2026, CDC immunogenicity analysis for the PEP program is ongoing, and an FDA submission for the PEP indication is targeted within the next 12 months.SIGA Technologies Financial Statement Overview
Summary
Income Statement
38
Negative
Balance Sheet
74
Positive
Cash Flow
62
Positive
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 93.78M | 94.60M | 138.72M | 139.92M | 110.78M | 133.67M |
| Gross Profit | 61.29M | 64.87M | 107.43M | 122.09M | 100.34M | 117.07M |
| EBITDA | 24.53M | 24.26M | 70.52M | 84.16M | 43.22M | 89.62M |
| Net Income | 20.26M | 23.30M | 59.21M | 68.07M | 33.90M | 69.45M |
Balance Sheet | ||||||
| Total Assets | 219.39M | 219.47M | 244.34M | 254.35M | 195.04M | 214.73M |
| Cash, Cash Equivalents and Short-Term Investments | 145.56M | 154.97M | 155.40M | 150.15M | 98.79M | 103.14M |
| Total Debt | 638.23K | 595.17K | 546.82K | 564.01K | 528.17K | 466.83K |
| Total Liabilities | 67.77M | 20.65M | 28.53M | 57.49M | 24.88M | 40.41M |
| Stockholders Equity | 151.62M | 198.82M | 215.80M | 196.86M | 170.16M | 174.31M |
Cash Flow | ||||||
| Free Cash Flow | 27.42M | 43.12M | 48.72M | 94.78M | 41.61M | 11.44M |
| Operating Cash Flow | 27.75M | 43.47M | 48.76M | 94.80M | 41.61M | 11.49M |
| Investing Cash Flow | -330.12K | -355.01K | -42.45K | -21.69K | 0.00 | -50.62K |
| Financing Cash Flow | -44.12M | -43.55M | -43.46M | -43.42M | -45.96M | -26.20M |
SIGA Technologies Technical Analysis
Positive
6.77
Price Trends
4.54
Positive
5.15
Negative
6.02
Negative
Market Momentum
-0.03
Negative
55.57
Neutral
68.47
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SIGA, the sentiment is Positive. The current price of 6.77 is above the 20-day moving average (MA) of 4.53, above the 50-day MA of 4.54, and above the 200-day MA of 6.02, indicating a neutral trend. The MACD of -0.03 indicates Negative momentum. The RSI at 55.57 is Neutral, neither overbought nor oversold. The STOCH value of 68.47 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SIGA.
SIGA Technologies Risk Analysis
SIGA Technologies disclosed 37 risk factors in its most recent earnings report. SIGA Technologies reported the most risks in the "Legal & Regulatory" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
SIGA Technologies Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
61 Neutral | $435.99M | 15.84 | -1.59% | ― | -29.89% | 93.33% | |
56 Neutral | $335.67M | -27.74 | 10.62% | ― | -22.07% | -58.28% | |
56 Neutral | $805.76M | -6.83 | 1.99% | ― | 61.13% | 92.51% | |
55 Neutral | $516.85M | -15.79 | 190.87% | ― | -7.30% | -3.31% | |
53 Neutral | $342.27M | -1.35 | -0.07% | ― | 12.19% | 1.97% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
SIGA
SIGA Technologies
4.68
-0.55
-10.48%
EBS
Emergent Biosolutions
8.45
2.05
32.03%
ESPR
Esperion
3.13
2.34
296.20%
ORGO
Organogenesis Holdings
2.66
-0.24
-8.28%
AQST
Aquestive Therapeutics
4.12
1.57
61.57%
SIGA Technologies Corporate Events
Dividends
SIGA Technologies Declares Special One-Time Cash Dividend
Positive
Mar 26, 2026
On March 26, 2026, SIGA Technologies, Inc. declared a special, one-time cash dividend of $0.60 per share of common stock, marking a return of capital to shareholders. The dividend will be paid on April 23, 2026 to investors of record as of April 7...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.